APELLIS PHARMACTDL (Germany) Top Insiders
| 1JK Stock | EUR 31.28 0.82 2.55% |
APELLIS PHARMACTDL employs about 767 people. The company is managed by 15 executives with a total tenure of roughly 118 years, averaging almost 7.0 years of service per executive, having 51.13 employees per reported executive. Examination of APELLIS PHARMACTDL's management performance can provide insight into the company performance.
| Cedric Francois CEO President, Chief Executive Officer, Co-Founder, Director |
APELLIS |
APELLIS PHARMACTDL Management Team Effectiveness
The company has return on total asset (ROA) of (0.4647) % which means that it has lost $0.4647 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (5.0711) %, meaning that it generated substantial loss on money invested by shareholders. APELLIS PHARMACTDL's management efficiency ratios could be used to measure how well APELLIS PHARMACTDL manages its routine affairs as well as how well it operates its assets and liabilities.APELLIS PHARMACTDL Workforce Comparison
APELLIS PHARMACTDL 0001 is number one stock in number of employees category among its peers. The total workforce of Biotechnology industry is presently estimated at about 1,804. APELLIS PHARMACTDL totals roughly 767 in number of employees claiming about 43% of stocks in Biotechnology industry.
APELLIS PHARMACTDL 0001 Benchmark Summation
Operator |
The output start index for this execution was zero with a total number of output elements of sixty-one. APELLIS PHARMACTDL 0001 Price Series Summation is a cross summation of APELLIS PHARMACTDL price series and its benchmark/peer.
APELLIS PHARMACTDL Notable Stakeholders
An APELLIS PHARMACTDL stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as APELLIS PHARMACTDL often face trade-offs trying to please all of them. APELLIS PHARMACTDL's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting APELLIS PHARMACTDL's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Cedric Francois | President, Chief Executive Officer, Co-Founder, Director | Profile | |
| Timothy Sullivan | Chief Financial Officer, Treasurer | Profile | |
| Pascal Deschatelets | Co-Founder, Chief Operating Officer | Profile | |
| Nicole Perry | Vice President - Finance | Profile | |
| Adam Townsend | Chief Commercial Officer | Profile | |
| Alec Machiels | Independent Director | Profile | |
| Thomas Lackner | Senior Vice President Head of Europe | Profile | |
| Paul Fonteyne | Independent Director | Profile | |
| A Dunlop | Independent Director | Profile | |
| Stephanie OBrien | Independent Director | Profile | |
| Gerald Chan | Independent Chairman of the Board | Profile | |
| David Watson | General Counsel, Vice President of Corporate Development | Profile | |
| Victoria Brown | Senior Vice President Program Team Lead – Systemic Chronic | Profile | |
| Federico Grossi | Chief Medical Officer | Profile | |
| Lukas Scheibler | Chief Innovation Officer | Profile |
About APELLIS PHARMACTDL Management Performance
The success or failure of an entity such as APELLIS PHARMACTDL 0001 often depends on how effective the management is. APELLIS PHARMACTDL management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of APELLIS management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the APELLIS management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Apellis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company was incorporated in 2009 and is based in Waltham, Massachusetts. APELLIS PHARMACT operates under Biotechnology classification in Germany and is traded on Frankfurt Stock Exchange. It employs 445 people.
APELLIS PHARMACTDL Workforce Analysis
Traditionally, organizations such as APELLIS PHARMACTDL use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare APELLIS PHARMACTDL within its industry.APELLIS PHARMACTDL Manpower Efficiency
Return on APELLIS PHARMACTDL Manpower
| Revenue Per Employee | 147.4K | |
| Revenue Per Executive | 7.5M | |
| Net Loss Per Employee | 600.1K | |
| Net Loss Per Executive | 30.7M |
Complementary Tools for APELLIS Stock analysis
When running APELLIS PHARMACTDL's price analysis, check to measure APELLIS PHARMACTDL's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy APELLIS PHARMACTDL is operating at the current time. Most of APELLIS PHARMACTDL's value examination focuses on studying past and present price action to predict the probability of APELLIS PHARMACTDL's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move APELLIS PHARMACTDL's price. Additionally, you may evaluate how the addition of APELLIS PHARMACTDL to your portfolios can decrease your overall portfolio volatility.
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk |